GLP-1 Use Surges to Record High as Access Expands

The use of GLP-1 medications for weight loss has reached an all-time high, with 11% of Americans now taking these drugs, a significant increase from 3% reported earlier in 2024, according to new Gallup data. This surge in adoption is facilitated by expanded access, including a temporary Medicare program and more straightforward online acquisition methods. Despite these access improvements, users continue to face high out-of-pocket costs for these medications.

In parallel, weight-loss drugs such as Wegovy and Mounjaro are demonstrably altering consumer spending patterns in the United Kingdom. Users of these medications are reporting substantial reductions in their expenditure on groceries and dining out. Research into these behavioral shifts indicates a notable move towards healthier food options and the purchase of products specifically designed to address potential side effects associated with the medications. However, the considerable expense associated with these drugs is identified as a primary reason for patients discontinuing their treatment.

The growing popularity and accessibility of GLP-1 medications signal a significant shift in both public health trends and consumer behavior. While these drugs offer potential benefits for weight management and related health conditions, their high cost presents a persistent challenge for widespread and sustained use. The impact on consumer spending, particularly in the grocery sector, suggests a broader economic ripple effect as these medications become more prevalent.